Breakthrough Cholesterol Treatment
Thomas discusses the efficacy of PCSK9 inhibitors in primary prevention, highlighting their potential in reducing ApoB levels. Despite being costly, these injectable drugs show promise in lowering LDL cholesterol through an LDL receptor mechanism, making them a viable option for high-risk individuals with atherosclerosis.In this clip
From this podcast
The Proof with Simon Hill
Preventing and treating cardiovascular disease (Lipid Series - Part 3) | Dr Thomas Dayspring
Related Questions